MedTrace Logo

Antiplatelet Effects of Evolocumab in Patients With Peripheral Arterial Disease

NCT03247972 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2024-02-16

Study results available
· View outcomes & findings →

Summary

This investigation will be conducted in subjects \>18 years of age with PAD. Platelet activation and aggregation, and biomarkers associated with platelet activation, oxidative stress, and inflammation will be assessed prior to initiation of study-HD statin therapy (baseline), after 8 weeks of high-dose statins and 24 hours and 8 weeks after high dose statin + evolocumab therapy

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Evolocumab

Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.

Sponsors & Collaborators

  • Inova Health Care Services

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-11
Primary Completion
2019-09-01
Completion
2019-10-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03247972 on ClinicalTrials.gov